Moderna's Coffee Break Science social media series brews up biopharma buzz
The social media series is Moderna’s way of demystifying biology ahead of the fall vaccination season.
Stay updated with breaking news from Blackstone Life Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The social media series is Moderna’s way of demystifying biology ahead of the fall vaccination season.
Blackstone has committed $300m to advance solrikitug for multiple indications.
/PRNewswire/ -- RevOpsis Therapeutics, a next-generation biopharmaceutical company spearheading innovation in ophthalmic therapies, announced today the...
Reports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)Prepares for launches of RSV vaccine and Spikevax® 2024-2025 formula; reaffirms 2024 expected product sales of approximately $4 billionInitiated three new clinical studies evaluating Moderna's investigational...
Novo continues to soar on GLP-1 sales, while Moderna and Regeneron look to pick up the pace.